Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial
Category: #health  By Mateen Dalal  Date: 2019-07-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ambrx partners with Bristol-Meyers to initiate Relaxin clinical trial

Ambrx will receive additional development payments with Bristol-Meyers’ initiation of the Phase 1 clinical trial for Relaxin

Ambrx Inc., a biopharmaceutical company focused on developing protein therapeutics, has recently announced that Bristol-Meyers Squibb has initiated a Phase 1 clinical trial in order to evaluate the safety, pharmacodynamics and pharmacokinetics of Relaxin, which is a long-acting and a potential heart failure treatment.

Reportedly, long-acting Relaxin happens to be an investigational biologic that is produced using the proprietary expanded genetic code platform from Ambrx. Heart failure affects 15 million people around the world and is a life-threatening and debilitating health condition.

President and CEO of Ambrx, Dr. Feng Tian said that the company believes long-acting Relaxin signifies a new therapeutic option to treat heart failure. The new trial is the second program from the company’s collaboration with Bristol-Myers Squibb which has been able to reach clinical testing, both of which have been enabled by the company’s platform technology.

The first program is a long acting FGF21 which is in Phase 2b to treat NASH. Both of these programs carry substantial value to Ambrx and the company appreciates Bristol-Myers Squibb as their partner, Tian added.

According to reports, under the 2011 Collaboration and License Agreement for Relaxin with Bristol-Myers Squibb, Ambrx will be paid a milestone payment with the initiation of the study. The terms of the agreement list that Ambrx will be eligible to receive additional payment for development including the royalties on annual net sales for any products related to Relaxin.

Apparently, Relaxin’s derivatives were developed using the expanded genetic code platform tech of Ambrx which incorporates non-native amino acid in the hormones. The non-natural amino acid is often used as chemical modification site for the engineering of precise protein which enhances Relaxin’s pharmaceutical or therapeutic properties and in this case, extends the circulating half-life of the hormone.

 

Source Credit- http://ambrx.com/wp-content/uploads/2019/07/Ambrx-BMS-Relaxin_-Ph1-Ambrx_final_new_BMS-edit.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

NantHealth & NantOmics launch AI platform for subtyping Lung Cancer
NantHealth & NantOmics launch AI platform for subtyping Lung Cancer
By Mateen Dalal

NantHealth, Inc., a personalized, evidence-based, next-generation healthcare company and NantOmics, LLC, one of the leading companies in molecular analysis, have reportedly launched an innovative AI platform for assisting pathologists in image-based ...

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...